ABBVIE INC.

ABBVNYSE • USD
260.87 USD
↗ 0.94 (0.36%)🟢PRE MARKET (AS OF 08:53 AM EDT)
🟢Market: OPEN

Shares of ABBVIE INC. (ABBV) are trading at $260.87. The stock presents a bearish profile across the board: technical indicators signal "Sell" and our fundamental models agree with a "Sell" rating. Notable factors include negative Return on Equity and a bullish Golden Cross on the moving averages. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.

Technical & fundamental data as of Oct 1, 2026.

Open?$260.25
High?$260.87
Low?$260.15
Prev. Close?$259.93
Volume?2.2K
Avg. Volume?4.1M
VWAP?$260.50
Rel. Volume?0.00x
Bid / Ask
Bid?$258.56 × 100
Ask?$262.00 × 500
Spread?$3.44
Midpoint?$260.28
Valuation & Ratios
Market Cap?459.3B
Shares Out?1.8B
Float?1.8B
Float %?100.0%
P/E Ratio?73.02
P/B Ratio?-77.39
EPS?$3.56
Dividend?2.61%
Ex-Dividend?2026-10-15
News
Profile
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
Employees
57.0K
Market Cap
459.3B
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2012-12-10
Address
1 NORTH WAUKEGAN ROAD
NORTH CHICAGO, IL 60064
Phone: (847) 932-7900
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
77
Z-Score?
57
Momentum?
75
Short Sent.?
57
Piotroski F-Score?6/9Mixed
Altman Z-Score?2.59Grey
Confidence?81%High
Full Fundamental Analysis →
Short InterestModerate
Short % of Float?1.10%Low
Short Interest?19.5M
Days to Cover?4.5
Free Float1.8B
Avg Daily Volume4.3M
Settlement Date2026-09-15
Financial Health
Current Ratio?0.81Weak
Quick Ratio?0.69Weak
Cash Ratio?0.16Low
Debt/Equity?-11.93Low
ValuationFAIRLY VALUEDvs 10 peers + S&P 500
Score
56/100
P/E?
Peers
33
S&P
6
73.0PRICEY▾
P/B?
Peers
100
S&P
97
-77.39CHEAP▾
P/S?
Peers
36
S&P
17
7.13HIGH▾
P/FCF?
Peers
40
S&P
39
25.2FAIR▾
EV/EBITDA?
Peers
70
S&P
35
17.8FAIR▾
EV/Sales?
Peers
36
S&P
16
8.13HIGH▾
Returns & Efficiency
ROE?
Peers
11
S&P
3
-106.0%WEAK▾
ROA?
Peers
44
S&P
42
4.7%FAIR▾
Cash Flow & Enterprise
FCF?$18.2B
Enterprise Value?$523.6B
Fundamentals ratios updated end of day